Hooked

Howard Brody is professor and director for the Institute for the Medical Humanities, University of Texas Medical Branch at Galveston. Prior to this appointment, Dr. Brody was University Distinguished Professor of family practice, and philosophy at Michigan State University, where he also sat on the faculty of the Center for Ethics and Humanities in the Life Sciences; he served as director of the Center from 1985-2000. Dr. Brody completed his residency in family practice at the University of Virginia Medical Center. He received his MD from the College of Human Medicine, Michigan State University, in 1976, and his PhD in Philosophy, also from Michigan State University, in 1977. He currently sits on the board of the American Society for Bioethics and the Humanities, and specializes in ethics and the doctor-patient relationship. He has authored five books, among them Stories of Sickness (2002) and The Placebo Response: How You Can Release the Body's Inner Pharmacy for Better Health (2000). For up-to-date news about the issues covered in Hooked, visit Dr. Brody's new blog.

Thoroughly documented, logically structured, and well written, [Brody's] book offers a good starting point for discussing ethical issues that impact us all. Recommended for all medical and public libraries.

• Chapter 1 Introduction: The Tipping PointPart 2 I. OverviewChapter 3 1. The Good, the Bad, and the Ugly: A Story of Two MedicationsChapter 4 2. An Ethical FrameworkPart 5 II. Specific Issues and ProblemsChapter 6 3. The Pharmaceutical Industry and the Free MarketChapter 7 4. Patents, Generic Drugs, and Academic ScienceChapter 8 5. Research and ProfitsChapter 9 6. Suppression of Research DataChapter 10 7. The Quality of Pharmaceutical ResearchChapter 11 8. The Drug Rep: Historical BackgroundChapter 12 9. The Drug Rep TodayChapter 13 10. The Influence of Drug Reps: What the Data ShowChapter 14 11. Continuing Medical EducationChapter 15 12. Professional Organizations and Journal AdvertisingChapter 16 13. The Industry and the ConsumerChapter 17 14. The FDA: From Patent Medicine to AIDS DrugsChapter 18 15. The FDA and the Industry, 1990-2004Part 19 III. Toward SolutionsChapter 20 16. Solutions: The Management and Divestment StrategiesChapter 21 17. Solutions Requiring Enhanced Professionalism in MedicineChapter 22 18. Solutions Requiring Regulatory ReformChapter 23 Epilogue: Industry Woes and Professional Opportunities